Stockwire

Fighting Fit

Divi’s Laboratories is a debt-free company & is far ahead of its competitions. Find out if it’s a good buy…

Divi’s, one of India’s biggest contract research and manufacturing services (CRAMS) player is often far ahead of its competition. The key differentiator between Divi’s and its peers is the former’s strong relationships with its customers that it boasts of. Not all of that is hot air. The company earns some of the highest margins in its industry (ebitda margin averaged 41.5 per cent in the previous three years). Being the lowest cost producer in some APIs certainly helps as does a dominant global market share in some other APIs (upwards of 50 percent). The company has posted an average ROCE of 36.5 per cent in the last five years. On the flip side, revenues are affected by the rupee movement (the recent rupee decline saw Divi’s come into favour). At a PE of 20 times, Divi’s still trade below its five year median On a PEG basis, this debt free company quotes at an attractive 0.46. Buy.



Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.


Other Categories

Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.

Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month